title: Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients.
abstract: An increasing body of experimental data suggests a role for 24,25(OH)2D3 in bone metabolism. The present study was carried out to assess a possible therapeutic role of this vitamin D metabolite in renal osteodystrophy. Twenty-two chronic dialysis patients, most of whom were previously maintained on 1 alpha (OH)D3 therapy, received additional treatment with 10 micrograms/day 24,25(OH)2D3 and were compared to 19 patients receiving 1 alpha (OH)D3 alone. Analysis of transiliac bone biopsies obtained at study entry and following 10-16 months of treatment revealed that the combined therapy produced a decrease in bone turnover. Specifically, the addition of 24,25(OH)2D3 inhibited an increase in trabecular bone volume (BV/TV) and suppressed osteoclastic parameters. Thus BV/TV increased from 26.2 +/- 8.6 to 32.1 +/- 7.5% (p < 0.01) in the 1 alpha (OH)D3 group, but it remained unchanged in the combined therapy group. In contrast, the eroded surface (ES/BS), the osteoclast surface (Oc.S/BS), and the osteoclast numbers were significantly suppressed in patients receiving both 24,25(OH)2D3 and 1 alpha (OH)D3, as compared with those receiving 1 alpha (OH)D3 alone (p < 0.01, p < 0.01, and p < 0.001, respectively). These improvements were independent of changes in 1 alpha (OH)D3 dosage. The extent of bone aluminium deposits was unrelated to the administration of 24,25(OH)2D3 or to its effect. 24,25(OH)2D3 therapy was not associated with any adverse effects.
authors.affiliation: Hadassah University Hospital, Jerusalem, Israel.
authors.forename: M M
authors.initials: MM
authors.lastname: Popovtzer
authors.forename: J
authors.initials: J
authors.lastname: Levi
authors.forename: Y
authors.initials: Y
authors.lastname: Bar-Khayim
authors.forename: S M
authors.initials: SM
authors.lastname: Shasha
authors.forename: G
authors.initials: G
authors.lastname: Boner
authors.forename: J
authors.initials: J
authors.lastname: Bernheim
authors.forename: C
authors.initials: C
authors.lastname: Chaimovitz
authors.forename: D
authors.initials: D
authors.lastname: Rubinger
authors.forename: U
authors.initials: U
authors.lastname: Gafter
authors.forename: D
authors.initials: D
authors.lastname: Gazit
mesh_terms: D015650:24,25-Dihydroxyvitamin D 3 / Q000097:blood / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D015519:Bone Density; D002118:Calcium / Q000097:blood; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D006887:Hydroxycholecalciferols; D010710:Phosphates; D015650:24,25-Dihydroxyvitamin D 3; D003404:Creatinine; D000469:Alkaline Phosphatase; D002118:Calcium; C008088:alfacalcidol